Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Johnson & Johnson (JNJ : NYSE)
 
 • Company Description   
Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.

Number of Employees: 141,700

 
 • Price / Volume Information   
Yesterday's Closing Price: $176.98 Daily Weekly Monthly
20 Day Moving Average: 7,695,066 shares
Shares Outstanding: 2,631.40 (millions)
Market Capitalization: $465,705.44 (millions)
Beta: 0.66
52 Week High: $186.69
52 Week Low: $155.72
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -2.51% 6.74%
12 Week 6.61% 19.82%
Year To Date 3.45% 26.39%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
ONE JOHNSON & JOHNSON PLZ
-
NEW BRUNSWICK,NJ 08933
USA
ph: 732-524-0400
fax: 732-214-0332
None http://www.jnj.com
 
 • General Corporate Information   
Officers
J. Duato - Chief Executive Officer
A. Gorsky - Executive Chairman; Board of Directors
J. J. Wolk - Chief Financial Officer
R. J. Decker Jr. - Controller and Chief Accounting Officer
M. C. Beckerle - Director

Peer Information
Johnson & Johnson (AGN.)
Johnson & Johnson (ABBV)
Johnson & Johnson (NVO)
Johnson & Johnson (LLY)
Johnson & Johnson (RHHBY)
Johnson & Johnson (JNJ)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: Large Cap Pharma
Sector: Medical
CUSIP: 478160104
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 07/20/22
Share - Related Items
Shares Outstanding: 2,631.40
Most Recent Split Date: 6.00 (2.00:1)
Beta: 0.66
Market Capitalization: $465,705.44 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 2.40%
Current Fiscal Quarter EPS Consensus Estimate: $2.55 Indicated Annual Dividend: $4.24
Current Fiscal Year EPS Consensus Estimate: $10.20 Payout Ratio: 0.43
Number of Estimates in the Fiscal Year Consensus: 9.00 Change In Payout Ratio: -0.03
Estmated Long-Term EPS Growth Rate: 5.94% Last Dividend Paid: NA - $0.00
Next EPS Report Date: 07/20/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: 17.35
Trailing 12 Months: 17.91
PEG Ratio: 2.92
Price Ratios
Price/Book: 6.23
Price/Cash Flow: 13.87
Price / Sales: 4.91
EPS Growth
vs. Year Ago Period: 3.09%
vs. Previous Quarter: 25.35%
Sales Growth
vs. Year Ago Period: 4.95%
vs. Previous Quarter: -5.56%
ROE
03/31/22 - 36.59
12/31/21 - 37.46
09/30/21 - 37.90
ROA
03/31/22 - 14.75
12/31/21 - 14.75
09/30/21 - 14.50
Current Ratio
03/31/22 - 1.39
12/31/21 - 1.35
09/30/21 - 1.34
Quick Ratio
03/31/22 - 1.14
12/31/21 - 1.12
09/30/21 - 1.11
Operating Margin
03/31/22 - 27.83
12/31/21 - 27.93
09/30/21 - 27.87
Net Margin
03/31/22 - 20.90
12/31/21 - 22.26
09/30/21 - 19.55
Pre-Tax Margin
03/31/22 - 22.35
12/31/21 - 24.29
09/30/21 - 21.42
Book Value
03/31/22 - 28.39
12/31/21 - 28.12
09/30/21 - 26.69
Inventory Turnover
03/31/22 - 2.90
12/31/21 - 2.93
09/30/21 - 2.99
Debt-to-Equity
03/31/22 - 0.39
12/31/21 - 0.41
09/30/21 - 0.43
Debt-to-Capital
03/31/22 - 27.86
12/31/21 - 28.83
09/30/21 - 30.01
 

Powered by Zacks Investment Research ©